DEA finalizes provisions regarding removal of waiver for prescribing medication for opioid use disorder treatment
The Drug Enforcement Administration today released a final rule implementing provisions from the Restoring Hope for Mental Health and Well-Being Act of 2022, which passed as part of the Consolidated Appropriations Act of 2023, eliminating the need for a separate waiver for qualified practitioners to dispense certain types of controlled substances for medications for opioid use disorder treatment, or MOUD. While the original requirements were amended by the SUPPORT Act of 2018 and changes were implemented in an interim final rule in 2020, the 2022 legislation struck the amended section from regulation, thus requiring DEA to respond to public comments on the interim final rule and update regulatory language accordingly.
Related News Articles
Headline
The Health Resources and Services Administration will award grants to rural hospitals and other providers from two areas of its Rural Communities Opioid…
Headline
The White House issued an executive order Jan. 29 to address substance use and addiction. The order establishes the White House Great American Recovery…
Headline
A Health Affairs study published Nov. 3 examined an increase in states banning prior authorizations in private insurance plans for opioid use disorder…
Headline
HHS awards $1.5 billion in opioid response grants to states, tribal communities The Department of Health and Human Services announced yesterday that it…
Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…